What is Kytopen?
Kytopen is a specialized biotechnology firm focused on the development of advanced non-viral cell engineering and gene delivery systems. At the core of its operations is the Flowfect platform, a proprietary technology designed to facilitate the efficient delivery of genetic materials—including DNA, mRNA, and gene-editing tools—into living cells. By utilizing a scalable and continuous flow process, Kytopen addresses critical bottlenecks in the production of next-generation cell therapies. The company's market position is defined by its ability to streamline complex laboratory workflows, making cell modification faster, more consistent, and highly suitable for industrial-scale biomanufacturing. Through its innovative engineering solutions, Kytopen serves as a vital partner for biotech organizations and research institutions aiming to accelerate therapeutic development and improve manufacturing yields.
How much funding has Kytopen raised?
Kytopen has raised a total of $33.6M across 2 funding rounds:
Angel/Seed
$3.6M
Series A
$30M
Angel/Seed (2019): $3.6M with participation from The Engine and Horizons Ventures
Series A (2021): $30M led by Horizon Ventures, Northpond Ventures, and Mass Ventures
Key Investors in Kytopen
Horizon Ventures
A venture capital firm specializing in early-stage funding for high-quality technology startups across internet, software, and telecommunications sectors.
Northpond Ventures
A prominent investment firm focused on supporting transformative companies within the science and technology landscape.
Mass Ventures
A firm dedicated to empowering entrepreneurs by providing essential resources, business planning guidance, and strategic connections to foster sustainable growth.
What's next for Kytopen?
With the recent infusion of capital, Kytopen is well-positioned to scale its operations and expand the reach of its Flowfect platform. The company's strategic roadmap likely involves deepening its footprint in the cell therapy manufacturing ecosystem, where the demand for efficient, non-viral delivery methods is rapidly increasing. By optimizing its continuous flow processes, Kytopen aims to reduce the cost and complexity associated with clinical-grade cell production. Future growth will likely focus on strategic partnerships with pharmaceutical developers and the further commercialization of its technology to support the next wave of genetic medicine. As the industry shifts toward more robust and scalable manufacturing standards, Kytopen's commitment to engineering excellence will be a key driver in its long-term value creation and market leadership.
See full Kytopen company page
